Immune Cells in the B-cell Lymphoma Microenvironment: From Basic Research to Clinical Applications

Overview

Journal Chin Med J (Engl)

Specialty General Medicine

Date 2024 Jan 25

PMID 38269619

Authors

Wenli Zhang

Mengmeng Liu

Wei Li

Yongping Song

Affiliations

Soon will be listed here.

Abstract

B-cell lymphoma is a group of hematological malignancies characterized by variable genetic and biological features and clinical behaviors. The tumor microenvironment (TME) is a complex network in tumors, which consists of surrounding blood vessels, extracellular matrix, immune and non-immune cells, and signaling molecules. Increasing evidence has shown that the TME, especially immune cells within, is a double-edged sword, acting either as a tumor killer or as a promoter of tumor progression. These pro-tumor activities are driven by subpopulations of immune cells that express typical markers but have unique transcriptional characteristics, making tumor-associated immune cells good targets for human anti-cancer therapy by ablating immunosuppressive cells or enhancing immune-activated cells. Thus, exploring the role of immune cells in the TME provides distinct insights for immunotherapy in B-cell lymphoma. In this review, we elucidated the interaction between immune cells and tumor cells and their function in the initiation, progression, and prognosis of B-cell lymphoma, from preclinical experiments to clinical trials. Furthermore, we outlined potential therapeutic approaches and discussed the potential clinical value and future perspectives of targeting immune cells in patients with B-cell lymphoma.

Citing Articles

Novel immunotherapeutic approaches in gastric cancer.

Yang M, Lin W, Huang J, Mannucci A, Luo H Precis Clin Med. 2024; 7(4):pbae020.

PMID: 39397869 PMC: 11467695. DOI: 10.1093/pcmedi/pbae020.

Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective.

Bakhtiyaridovvombaygi M, Yazdanparast S, Kheyrandish S, Safdari S, Amiri Samani F, Sohani M Biomark Res. 2024; 12(1):66.

PMID: 39020411 PMC: 11253502. DOI: 10.1186/s40364-024-00610-z.

References

Horwitz S, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M . Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2017; 131(8):888-898. PMC: 5824337. DOI: 10.1182/blood-2017-08-802470. View

Tan R, Nie M, Long W . The role of B cells in cancer development. Front Oncol. 2022; 12:958756. PMC: 9403891. DOI: 10.3389/fonc.2022.958756. View

Yang H, Yan M, Li W, Xu L . SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma. J Transl Med. 2022; 20(1):140. PMC: 8939174. DOI: 10.1186/s12967-022-03342-6. View

Tawbi H, Schadendorf D, Lipson E, Ascierto P, Matamala L, Castillo Gutierrez E . Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022; 386(1):24-34. PMC: 9844513. DOI: 10.1056/NEJMoa2109970. View

Crump M, Neelapu S, Farooq U, Van den Neste E, Kuruvilla J, Westin J . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808. PMC: 5649550. DOI: 10.1182/blood-2017-03-769620. View

Li W, Wang Y, Zhao H, Zhang H, Xu Y, Wang S . Identification and transcriptome analysis of erythroblastic island macrophages. Blood. 2019; 134(5):480-491. PMC: 6676133. DOI: 10.1182/blood.2019000430. View

Buatois V, Johnson Z, Salgado-Pires S, Papaioannou A, Hatterer E, Chauchet X . Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. Mol Cancer Ther. 2018; 17(8):1739-1751. PMC: 6072583. DOI: 10.1158/1535-7163.MCT-17-1095. View

He Q, Jiang X, Zhou X, Weng J . Targeting cancers through TCR-peptide/MHC interactions. J Hematol Oncol. 2019; 12(1):139. PMC: 6921533. DOI: 10.1186/s13045-019-0812-8. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

10.

Ansell S, Maris M, Lesokhin A, Chen R, Flinn I, Sawas A . Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. Clin Cancer Res. 2021; 27(8):2190-2199. DOI: 10.1158/1078-0432.CCR-20-3706. View

11.

Kwon D, Kim S, Kim P, Go H, Jeong Nam S, Paik J . Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. Histopathology. 2015; 68(7):1079-89. DOI: 10.1111/his.12882. View

12.

Chevalier N, Mueller M, Mougiakakos D, Ihorst G, Marks R, Schmitt-Graeff A . Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment. Leuk Lymphoma. 2016; 57(9):2150-60. DOI: 10.3109/10428194.2015.1135432. View

13.

Bannerji R, Arnason J, Advani R, Brown J, Allan J, Ansell S . Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022; 9(5):e327-e339. PMC: 10681157. DOI: 10.1016/S2352-3026(22)00072-2. View

14.

Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani P . Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018; 36(14):1428-1439. PMC: 6075855. DOI: 10.1200/JCO.2017.76.0793. View

15.

Myklebust J, Irish J, Brody J, Czerwinski D, Houot R, Kohrt H . High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood. 2013; 121(8):1367-76. PMC: 3578953. DOI: 10.1182/blood-2012-04-421826. View

16.

Myers J, Miller J . Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2020; 18(2):85-100. PMC: 8316981. DOI: 10.1038/s41571-020-0426-7. View

17.

Gordon S, Maute R, Dulken B, Hutter G, George B, McCracken M . PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017; 545(7655):495-499. PMC: 5931375. DOI: 10.1038/nature22396. View

18.

Marini O, Spina C, Mimiola E, Cassaro A, Malerba G, Todeschini G . Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. Oncotarget. 2016; 7(19):27676-88. PMC: 5053680. DOI: 10.18632/oncotarget.8507. View

19.

Tuscano J, Maverakis E, Groshen S, Tsao-Wei D, Luxardi G, Merleev A . A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma. Clin Cancer Res. 2019; 25(23):7004-7013. PMC: 7354236. DOI: 10.1158/1078-0432.CCR-19-0438. View

20.

Betsch A, Rutgeerts O, Fevery S, Sprangers B, Verhoef G, Dierickx D . Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly. Blood Rev. 2018; 32(6):490-498. DOI: 10.1016/j.blre.2018.04.006. View